Switching Outpatients With Bipolar or Schizoaffective Disorders and Substance Abuse From Their Current Antipsychotic to Aripiprazole
The DOI matches its Crossref record.
Abstract
OBJECTIVE: Substance abuse is extremely common in patients with bipolar disorders, although minimal data are available on the treatment of this important clinical population. Aripiprazole is an atypical antipsychotic that is approved for the treatment of mania and that has a novel mechanism of action, acting as a dopamine-2 receptor partial agonist, thereby increasing dopamine release in some parts of the brain and decreasing dopa-mine release in other brain regions. Dopamine release is implicated in substance use, and both dopaminergic agonists and antagonists have been examined for the treatment of substance abuse. To our knowledge, dopa-mine receptor partial agonists have not been investigated for treatment of substance abuse in humans. METHOD: Twenty antipsychotic-treated patients with bipolar or schizoaffective disorder and current substance abuse were switched to open-label aripipra-zole using an overlap and taper method. At baseline, diagnoses were confirmed using the Mini-International Neuropsychiatric Interview based on DSM-IV criteria. Psychiatric symptoms, side effects, and substance use and craving were assessed over 12 weeks. Psychiatric symptoms were assessed with the Hamilton Rating Scale for Depression (HAM-D), Young Mania Rating Scale (YMRS), and Brief Psychiatric Rating Scale (BPRS). Substance craving was assessed with visual analogue scales, and side effects were monitored using the Abnormal Involuntary Movement Scale, Simpson-Angus Scale, Barnes Akathisia Scale, and patient report. Study enrollment was from April 2003 to February 2004. RESULTS: Significant baseline-to-exit improvement in HAM-D (p = .002), YMRS (p = .021), and BPRS (p = .000) scores were observed without a significant change in antipsychotic-induced side effect scales. In 17 participants with current alcohol dependence, significant reductions in dollars spent on alcohol (p = .042) and alcohol craving (p = .003) were found. In 9 participants with cocaine-related disorders, significant reductions in cocaine craving (p = .014), but not use, were found. CONCLUSION: A change to aripiprazole was associated with symptomatic improvement. Limitations of the study include a small sample size, high attrition, and an open-label design. Controlled trials in dual-diagnosis patients are needed to confirm these findings.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aripiprazole has level 4 evidence to decrease craving of alcohol, but not consumption, and level 4 evidence to decrease cocaine use in polysubstance users.719”
Citations
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Lingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332
“In an open-label study of 20 patients with bipolar disorder or schizoaffective disorder, a switch to aripiprazole resulted in improved depression, mania and BPRS scores as well as reduction in cocaine and alcohol craving, and amount spent on alcohol, but not cocaine use (Brown et al., 2005) (IIb).”
BackgroundThe prevalence and significance of substance use disorders in bipolar type I and II disorder
Cerullo, M. A., & Strakowski, S. M. (2007) · Substance Abuse Treatment, Prevention, and Policy · doi:10.1186/1747-597x-2-29 · Cited by 195
Unique Effects of Clozapine: A Pharmacological Perspective
Khokhar, J. Y., Henricks, A. M., Sullivan, E. D. K., & Green, A. I. (2018) · Advances in Pharmacology · doi:10.1016/bs.apha.2017.09.009 · Cited by 182
Treatments for Patients With Dual Diagnosis: A Review
Tiet, Q. Q., & Mausbach, B. (2007) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2007.00336.x · Cited by 169
Substance abuse and schizophrenia: Pharmacotherapeutic intervention
Green, A. I., Noordsy, D. L., Brunette, M. F., & O’Keefe, C. D. (2007) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2007.01.008 · Cited by 175
Maremmani, I., Perugi, G., Pacini, M., & Akiskal, H. S. (2006) · Journal of Affective Disorders · doi:10.1016/j.jad.2006.02.022 · Cited by 120
Aripiprazole Blocks Reinstatement of Cocaine Seeking in an Animal Model of Relapse
Feltenstein, M. W., Altar, C. A., & See, R. E. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.04.010 · Cited by 106
Goldstein, B. I., & Bukstein, O. G. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09r05222gry · Cited by 88
Screening for depression and anxiety disorders in primary care patients
Bunevičius, A., Pečeliūnienė, J., Mickuvienė, N., Valius, L., & Bunevičius, R. (2006) · Depression and Anxiety · doi:10.1002/da.20274 · Cited by 104
“The MINI is a validated instrument for evaluation of emotional disorders in psychiatric populations [Brown et al., 2005; Cassano et al., 2004] and in general medical populations [Bunevicius et al., 2005; Friedman et al., 2005].”
Alcohol Use Disorder and Schizophrenia or Schizoaffective Disorder
Archibald, L. J., Brunette, M. F., Wallin, D. J., & Green, A. I. (2019) · Alcohol research · doi:10.35946/arcr.v40.1.06 · Cited by 125
REVIEW: New developments in the pharmacotherapy of cocaine abuse
Preti, A. (2007) · Addiction Biology · doi:10.1111/j.1369-1600.2007.00061.x · Cited by 79
Comorbid Bipolar and Alcohol Use Disorder—A Therapeutic Challenge
Grunze, H., Schaefer, M., Scherk, H., Born, C., & Preuss, U. W. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.660432 · Cited by 103
Coffin, P. O., Santos, G., Das, M., Santos, D. M., Huffaker, S., Matheson, T., Gasper, J., Vittinghoff, E., & Colfax, G. N. (2013) · Addiction · doi:10.1111/add.12073 · Cited by 67
“(20– 24)Finally, pilot clinical studies demonstrated reduced use or craving for other psychostimulants.(25, 26)”
BackgroundCharacterization of aripiprazole partial agonist activity at human dopamine D3 receptors
Tadori, Y., Forbes, R. A., McQuade, R. D., & Kikuchi, T. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.09.008 · Cited by 69
Freeman, M. P. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.8157su1c.01 · Cited by 68
Thomsen, M., Fink‐Jensen, A., Woldbye, D. P. D., Wörtwein, G., Sager, T. N., Holm, R., Pepe, L. M., & Caine, S. B. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1245-1 · Cited by 67
“Those recent clinical findings are in apparent discordance with earlier findings from open studies in patients with schizophrenia or bipolar/schizoaffective disorders, in which chronic aripiprazole was reported to decrease cocaine craving and/or use (Brown et al. 2005; Beresford et al. 2005).”
Comparison of Olanzapine to Risperidone in Substance‐Abusing Individuals with Schizophrenia
Akerele, E., & Levin, F. R. (2007) · The American Journal on Addictions · doi:10.1080/10550490701389658 · Cited by 63
Aripiprazole maintenance increases smoked cocaine self-administration in humans
Haney, M., Rubin, E., & Foltin, R. W. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2231-6 · Cited by 62
“Although aripiprazole did not alter cocaine use in bipolar or schizoaffective patients with cocaine-related disorders (Brown et al. 2005), an open-label trial showed that aripiprazole decreased cocaine use in cocaine-dependent schizophrenic patients (Beresford et al. 2005).”
Brunette, M. F., Dawson, R., O’Keefe, C. D., Narasimhan, M., Noordsy, D. L., Wojcik, J., & Green, A. I. (2011) · Journal of Dual Diagnosis · doi:10.1080/15504263.2011.570118 · Cited by 67
Cuomo, I., Kotzalidis, G. D., Persis, S. D., Piacentino, D., Perrini, F., Amici, E., & Filippis, S. D. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s171002 · Cited by 60
“48 Aripiprazole reduced cocaine craving in patients with schizophrenia comorbid with SUD 49,50 and with cocaine use disorder.”
Treatment of patients comorbid for addiction and other psychiatric disorders
Brady, K. T., Verduin, M. L., & Tolliver, B. K. (2007) · Current Psychiatry Reports · doi:10.1007/s11920-007-0048-0 · Cited by 64
“Aripiprazole was reported to reduce alcohol and cocaine craving, as well as to result in fewer positive urine toxicology screens in a small, open-label trial of schizophrenic individuals with cocaine dependence [17]; similar findings have been reported with aripiprazole in bipolar and schizoaffective disorders with co…”
BackgroundResultPharmacotherapy of Addictive Disorders
Ross, S., & Peselow, E. D. (2009) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181a91655 · Cited by 65
“Aripiprazole, a partial dopaminergic agonist used to treat schizophrenia, has been associated with decreased cocaine craving in open-label trials of patients with schizophrenia and comorbid cocaine dependence.(140,141) Antagonism at the DAT remains a theoretical point of intervention, whereas nonselective DA receptor…”
BackgroundEliciting adverse effects data from participants in clinical trials
Allen, E. N., Chandler, C. I., Mandimika, N., Leisegang, C., & Barnes, K. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000039.pub2 · Cited by 52
The clinical management of bipolar disorder complexity using a stratified model
Malhi, G. S., Bargh, D. M., Cashman, E., Frye, M. A., & Gitlin, M. (2012) · Bipolar Disorders · doi:10.1111/j.1399-5618.2012.00993.x · Cited by 49
“Second-line options include adjunctive lamotrigine (level IV) (146, 147) and aripiprazole (level IV) (148), both of which have preliminary evidence of bimodal efficacy in the treatment of affective BD symptoms and substance cravings.”
BackgroundCombination Therapy for Manic Phases: A Critical Review of a Common Practice
Geoffroy, P. A., Etain, B., Henry, C., & Bellivier, F. (2012) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12017 · Cited by 47
“An open study investigated replacing the previous antipsychotic treatment with aripiprazole in patients treated for BD or schizoaffective disorder who displayed signs of substance abuse; this treatment resulted in a significant reduction in the craving for alcohol and cocaine over a 3-month follow-up [54].”
Nicola, M. D., Risio, L. D., Pettorruso, M., Caselli, G., Crescenzo, F. D., Swierkosz-Lenart, K., Martinotti, G., Camardese, G., Giannantonio, M. D., & Janiri, L. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.06.023 · Cited by 53
“A small, 12-week, open-label study tested the efficacy of aripiprazole in BD patients with polysubstance abuse (alcohol, cocaine, opioids and cannabis) and found that it significantly improved mood symptoms, decreased alcohol and cocaine craving and reduced money spent per week for alcohol (Brown et al., 2005).”
BackgroundAripiprazole blocks acute self-administration of cocaine and is not self-administered in mice
Sørensen, G., Sager, T. N., Petersen, J. H., Brennum, L. T., Thøgersen, P., Bengtsen, C. H., Thomsen, M., Wörtwein, G., Fink‐Jensen, A., & Woldbye, D. P. D. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1069-z · Cited by 50
“In line with our results, clinical studies have reported that aripiprazole reduced cocaine craving and decreased the subject-rated effect of d-amphetamine (Beresford et al. 2005; Brown et al. 2005 ; L ile et al.2005; Stoops et al. 2006).”
InfluentialEfficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review
Fountoulakis, K. Ν., & Vieta, E. (2009) · Annals of General Psychiatry · doi:10.1186/1744-859x-8-16 · Cited by 46
“000) scores as well as a decrease in alcohol and substance craving without a significant change in antipsychotic-induced side effect scales [93].”
Bipolar Disorder and Substance Abuse
Brown, E. S. (2005) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2005.01.004 · Cited by 47
Self-citationEFFECTS OF ARIPIPRAZOLE ON ALCOHOL INTAKE IN AN ANIMAL MODEL OF HIGH-ALCOHOL DRINKING
Ingman, K., KUPILA, J., Hyytiä, P., & Korpi, E. R. (2006) · Alcohol and Alcoholism · doi:10.1093/alcalc/agl037 · Cited by 50
“, 2005) might provide a novel therapeutic approach in treating patients abusing alcohol (Brown et al., 2005; Warsi et al., 2005).”
Antipsychotic Drug Treatment of Schizophrenic Patients with Substance Abuse Disorders
San, L., Arranz, B., & Martínez-Raga, J. (2007) · European Addiction Research · doi:10.1159/000104886 · Cited by 48
“Of the 6 patients that completed the open-label study, positive urine tests dropped significantly after 2 weeks, and significant declines in mean cocaine and alcohol craving scores were noted after the studied period. In an additional 12-week open-label study, 20 antipsychotic-treated patients with bipolar or schizoaf…”
MethodDrugs currently in Phase II clinical trials for cocaine addiction
Kim, J. H., & Lawrence, A. J. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.915312 · Cited by 43
“For example, whilst aripiprazole appears ineffective in promoting abstinence in nonco-morbid cocaine dependents, it seems quite effective in reducing cocaine use in co-morbid schizophrenic patients [92,93].”
BackgroundBeaulieu, S., Saury, S., Sareen, J., Tremblay, J., Schütz, C. G., McIntyre, R. S., & Schaffer, A. (2012) · Annals of Clinical Psychiatry · doi:10.1177/104012371202400105 · Cited by 38
Stoops, W. W. (2006) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.14.4.413 · Cited by 41
Mood stabilizers for patients with bipolar disorder: the state of the art
Altamura, A. C., Lietti, L., Dobrea, C., Benatti, B., Arici, C., & Dell’Osso, B. M. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.181 · Cited by 39
Repeated aripiprazole administration attenuates cocaine seeking in a rat model of relapse
Feltenstein, M. W., Do, P. H., & See, R. E. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1671-8 · Cited by 38
“…et al. 2007; Jerlhag 2008; Li et al. 2009; Schwabe and Koch 2007; Sørensen et al. 2008; Wee et al. 2007) and clinical (Beresford et al. 2005; Brown et al. 2005; Lile et al. 2005; Stoops et al. 2006) data indicates that DA partial agonist compounds such as aripiprazole may be effective…”
InfluentialTreatment of co-occurring alcohol and other drug use disorders.
Arias, A. J., & Kranzler, H. R. (2008) · PubMed Central · Cited by 41
Effects of Aripiprazole on Subjective and Physiological Responses to Alcohol
Kranzler, H. R., Covault, J., Pierucci‐Lagha, A., Chan, G., Douglas, K., Arias, A. J., & Oncken, C. A. (2008) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2007.00608.x · Cited by 34
“In a series of 20 outpatients with bipolar or schizoaffective disorder and comorbid substance abuse whose antipsychotic medication was switched to openlabel aripiprazole, there was a marked improvement in symptoms of both mania and depression, with no change in adverse effects (Brown et al., 2005).”
Pharmacotherapies for co‐occurring substance use and bipolar disorders: A systematic review
Coles, A. S., Sasiadek, J., & George, T. P. (2019) · Bipolar Disorders · doi:10.1111/bdi.12794 · Cited by 39
“Aripiprazole: 1 Study Brown et al, 2005 27 N = 19 participants with bipolar disorder I or II or schizoaffective disorder and concurrent substance dependence.”
BackgroundBergman, J. (2008) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0014398 · Cited by 34
Antipsychotic switching in bipolar disorders: a systematic review
Grande, I., Bernardo, M., Bobes, J., Saiz-Ruiz, J., Álamo, C., & Vieta, E. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713001168 · Cited by 30
“(Brown et al., 2005) 19 BD-I/II patients on current substance abuse (out of 20) Retrospective open-label study with cross-taper switch from A to aripiprazole 12 Efficacy: YMRS, HDRS, BPRS, substance craving VAS, dollars spent, substance use Safety: BARS, SAS, AIMS Significant clinical improvement without changes in to…”
InfluentialKoola, M. M., Wehring, H. J., & Kelly, D. L. (2012) · Journal of Dual Diagnosis · doi:10.1080/15504263.2012.647345 · Cited by 34
“There is some evidence that clozapine and aripiprazole may be associated with less craving (Zimmet et al., 2000; Brown et al., 2005), while other reports suggest that risperidone, olanzapine, and quetiapine are associated with less craving than first-generation medications.”
ResultBeresford, T. P., Buchanan, J., Thumm, E. B., Emrick, C. D., Weitzenkamp, D. A., & Ronan, P. J. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000789 · Cited by 31
Stoops, W. W., Lile, J. A., Lofwall, M. R., & Rush, C. R. (2007) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990701651556 · Cited by 29
“Aripiprazole has been shown to decrease the number of cocaine-positive urines in a small study in schizophrenic patients (16) and to reduce cocaine craving in patients with bipolar or schizoaffective disorder (17).”
BackgroundSani, G., Kotzalidis, G. D., Vöhringer, P., Pucci, D., Simonetti, A., Manfredi, G., Savoja, V., Tamorri, S. M., Mazzarini, L., Pacchiarotti, I., et al. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318287019c · Cited by 27
Gholampour, H., Moezi, L., & Shafaroodi, H. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.07.032 · Cited by 27
Aripiprazole and Ropinirole Treatment for Cocaine Dependence: Evidence from a Pilot Study
Meini, M., Moncini, M., Cecconi, D., Cellesi, V., Biasci, L., Simoni, G., Ameglio, M., Pellegrini, M., Forgione, R. N., & Rucci, P. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211796150783 · Cited by 27
“Moreover, two studies carried out in patients with psychiatric disorders and comorbid cocaine use reported a significant reduction in craving for cocaine during treatment with aripriprazole [38] [39].”
BackgroundWai, J. M., Shulman, M., & Nunes, E. V. (2021) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615373970.kb44 · Cited by 23
Possible new ways in the pharmacological treatment of bipolar disorder and comorbid alcoholism
Garay, R. (2010) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s6741 · Cited by 23
“To our knowledge, no other studies of aripiprazole in bipolar disorders with comorbid alcoholism were conducted since the one of Brown and colleagues.(35) N eu ro ps yc hi at ric D is ea se a nd T re at m en t d ow nl oa de d fr om h ttp s: //w w w .”
Pharmacotherapy of Co-Occurring Schizophrenia and Substance Use Disorders
Akerman, S. C., Brunette, M. F., Noordsy, D. L., & Green, A. I. (2014) · Current Addiction Reports · doi:10.1007/s40429-014-0034-7 · Cited by 25
A UK consensus on the administration of aripiprazole for the treatment of mania
Aitchison, K. J., Bienroth, M., Cookson, J., Gray, R. J., Haddad, P. M., Moore, B. A., Ratna, L., Sullivan, G., Taylor, D. M., Taylor, M., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108098820 · Cited by 23
Fagiolini, A. M., Brugnoli, R., Sciascio, G. D., Filippis, S. D., & Maina, G. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1013029 · Cited by 23
“There have been a number of clinical trials as well as several case reports and series investigating switching from existing antipsychotic therapy to aripiprazole [23-38].”
BackgroundPharmacological Treatment of Schizophrenia and Co-Occurring Substance Use Disorders
Smelson, D. A., Dixon, L. B., Craig, T., Remolina, S., Batki, S. L., Niv, N., & Owen, R. R. (2008) · CNS Drugs · doi:10.2165/00023210-200822110-00002 · Cited by 25
Lile, J. A., Stoops, W. W., Hays, L. R., & Rush, C. R. (2008) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990802308262 · Cited by 21
“For example, in schizophrenic patients, aripiprazole decreased the number of cocaine-positive urines (22), and in another study in patients with bipolar or schizoaffective disorder, aripiprazole reduced cocaine craving (23), suggesting that aripiprazole would be useful in cocainedependent individuals with co-existing…”
Protocols of Dual Diagnosis Intervention in Schizophrenia
Roncero, C., Barral, C., Grau‐López, L., Bachiller, D., Szerman, N., Casas, M., & Ruiz, P. (2011) · Addictive Disorders & Their Treatment · doi:10.1097/adt.0b013e318227ecdc · Cited by 29
Tratamiento de adicciones en Colombia
Hernández, D. C. (2010) · Revista Colombiana de Psiquiatría · doi:10.1016/s0034-7450(14)60274-2 · Cited by 33
Reducing Addiction in Bipolar Disorder via Hacking the Dopaminergic System
Grunze, H., Csehi, R., Born, C., & Barabássy, Á. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.803208 · Cited by 23
“Furthermore, a study involved patients with comorbid BD/schizoaffective disorder and SUD who were switched to aripiprazole (40).”
BackgroundPharmacological Treatment of Bipolar Disorder with Comorbid Alcohol Use Disorder
Naglich, A. C., Adinoff, B. H., & Brown, E. S. (2017) · CNS Drugs · doi:10.1007/s40263-017-0449-5 · Cited by 23
“Brown and colleagues conducted a 12-week, open-label, pilot study in which 17 patients with BD or schizoaffective disorder and comorbid substance use disorders were switched from various antipsychotics to aripiprazole [23].”
BackgroundSelf-citationPae, C., Han, C., Bahk, W., Lee, S.-J., Patkar, A. A., & Masand, P. S. (2021) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2021.19.3.434 · Cited by 18
“iperidone had effects on craving, whereas numerous studies have reported the beneficial effects of oral aripiprazole on amelioration of craving of alcohol in human [74] and”
BackgroundSepede, G., Di lorio, G., Lupi, M., Sarchione, F., Acciavatti, T., Fiori, F., Santacroce, R., Martinotti, G., Gambi, F., & Di Giannantonio, M. (2014) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000011 · Cited by 16
“A study conducted on bipolar and schizoaffective patients with current SUD evidenced a significant improvement in mood symptoms and substance craving after shifting from other antipsychotics to aripiprazole in 9 patients with cocaine-related disorders.(30) The role of bupropion in the treatment of CDD has been reviewe…”
BackgroundPediatric Uptake of a Newly Available Antipsychotic Medication
Penfold, R. B., Kelleher, K. J., Wang, W., Strange, B., & PAJER, K. A. (2010) · PEDIATRICS · doi:10.1542/peds.2009-1288 · Cited by 15
Proposed strategies for successful clinical management with aripiprazole
Mago, R. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.8.1279 · Cited by 16
“With the exception of a small, open-label, pilot study [54] , no report is available on switching patients with bipolar disorders to aripiprazole.”
BackgroundAuxilia, A. M., Buoli, M., Caldiroli, A., Carnevali, G. S., Tringali, A. G. M., Nava, R., Clerici, M., & Capuzzi, E. (2023) · Biomedicines · doi:10.3390/biomedicines11020314 · Cited by 16
“Some authors reported that switching from other antipsychotics to aripiprazole may result in symptom improvement in patients with bipolar or schizoaffective disorders and comorbid substance misuse [71,72].”
BackgroundAttenuation of reinforcing and psychomotor stimulant effects of amphetamine by aripiprazole
Bäckström, P., Etelälahti, T. J., & Hyytiä, P. (2010) · Addiction Biology · doi:10.1111/j.1369-1600.2010.00223.x · Cited by 12
“…effects of alcohol (Kranzler et al. 2008), and there is also evidence that it may be effective in decreasing craving for and use of alcohol in alcohol-dependent patients (Brown et al. 2005; Martinotti, Di Nicola & Janiri 2007; Anton et al. 2008), although the results are still inconclusive.”
ResultSepede, G., Lorusso, M., Spano, M. C., Nanno, P. D., Iorio, G. D., & Giannantonio, M. D. (2018) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000297 · Cited by 11
Erdoğan, A., & Yurteri, N. (2010) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 10
The pharmacotherapeutic management of comorbid bipolar disorder and alcohol use disorder
Grunze, H., & Soyka, M. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2083500 · Cited by 12
“It has been suggested, based upon retrospective data, that similar to aripiprazole [135], quetiapine might reduce craving in persons with BD and comorbid cocaine use [136].”
BackgroundCrocq, M. A., Camus, V., Millet, B., Glickman, J., Azorin, J., Krebs, M., Limosin, F., Costentin, J., & Daléry, J. (2008) · L Encéphale · doi:10.1016/j.encep.2007.12.004 · Cited by 9
Le point sur l’addiction à la cocaïne et au crack
Charles‐Nicolas, A., Lacoste, J., & Ballon, N. (2009) · Annales Médico-psychologiques revue psychiatrique · doi:10.1016/j.amp.2009.06.016 · Cited by 9
“ayant également un abus ou une dépendance à la cocaïne [6].”
BackgroundEfficacy of Aripiprazole in Comorbid Addiction in Bipolar Disorder
Geoffroy, P. A., Goddefroy, G., Rolland, B., & Cottencin, O. (2012) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2012.00301.x · Cited by 8
“This approach resulted in a significant reduction in the craving for alcohol and cocaine over a 3-month follow-up [10].”
BackgroundOrtiz, C., Roncero, C., Miquel, L., & Casas, M. (2011) · Adicciones · doi:10.20882/adicciones.168 · Cited by 12
Woo, Y. S., Bahk, W., Park, Y., Chung, S., Yoon, B.-H., Won, S., Lee, J. G., Lee, H.-B., Kim, W. K., Jeong, J., et al. (2016) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000136 · Cited by 9
“However, only limited research has been carried out to date on the effectiveness of switching to aripiprazole from other AAPs in bipolar patients with subsyndromal symptoms or intolerance to current AAPs (Brown et al., 2005; Chen et al., 2012).”
BackgroundDiagnostic and Treatment Considerations: Bipolar Patients with Comorbid Substance Use Disorders
Salloum, I. M., Douaihy, A. B., & Williams, L. B. (2008) · Psychiatric Annals · doi:10.3928/00485713-20081101-09 · Cited by 8
An Open-Label Trial of Aripiprazole Treatment in Dual Diagnosis Individuals: Safety and Efficacy
McRae‐Clark, A. L., Verduin, M. L., Tolliver, B. K., Carter, R. E., Wahlquist, A. E., Brady, K. T., Cluver, J. S., & Anderson, S. (2009) · Journal of Dual Diagnosis · doi:10.1080/15504260802620210 · Cited by 8
The combination of escitalopram and aripiprazole: Investigation of psychomotor effects in rats
Hudson, R., Zhou, Y., & Leri, F. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117732515 · Cited by 11
“More specifically, because ARI improves hedonic functions in substance-dependent (Brown et al., 2005; Brunetti et al., 2012; Janiri et al., 2007; Martinotti et al., 2009), schizophrenic (Liemburg et al., 2011) and bipolar patients (Mazza et al., 2009), it is reasonable to anticipate that ARI may…”
BackgroundVeznedaroğlu, B., Dılbaz, N., Uzun, Ö., & Işık, E. (2018) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125318772712 · Cited by 8
Novel Pharmacotherapeutic Interventions for Cannabis Use Disorder
Mason, B. L., Mustafa, A., Filbey, F. M., & Brown, E. S. (2016) · Current Addiction Reports · doi:10.1007/s40429-016-0094-y · Cited by 7
Self-citationSantorelli, M., Miuli, A., Pettorruso, M., Carlo, F. D., Berardis, D. D., Sensi, S. L., Martinotti, G., Clerici, M., & Giannantonio, M. D. (2024) · Current Neuropharmacology · doi:10.2174/1570159x23666241023115252 · Cited by 8
“…positive results were found in other studies that indicated a reduction of positive urine dosage [32], reduction of the quantity of substance used [39], reduction in money spent on substances [35, 39], reduction of withdrawal symptoms [37], and reduction of the severity of addiction [36].”
InfluentialCariprazine in Bipolar Disorder and Substance Use: A Dual Approach to Treatment?
Pardossi, S., Cuomo, A., Koukouna, D., Pinzi, M., & Fagiolini, A. M. (2024) · Pharmaceuticals · doi:10.3390/ph17111464 · Cited by 6
“Focusing on drugs more similar to cariprazine, which share partial agonism at D2 receptors, one study highlighted that patients with comorbid BD and alcohol use disorder showed symptomatic improvement when switched to aripiprazole [65].”
Liu, Y., Bao, Y., Sun, H., Beveridge, T. J. R., Li, S., Di, X.-L., Yang, F., & Lü, L. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181e78a2b · Cited by 6
“Similar results were also found in antipsychotic agentYtreated patients with bipolar or schizoaffective disorder and current cocaine or alcohol abuse.(68) To date, only one case report has documented the long-term effects of aripiprazole on nicotine dependence in a patient with a history of major depressive disorder.”
ResultChen, S.-F., & Shen, Y. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001087 · Cited by 6
“One such study found that replacing an antipsychotic with aripiprazole resulted in improved symptoms in patients with concomitant schizoaffective disorder and substance use disorder.(4) Another similar study showed that aripiprazole reduced craving in patients with concomitant schizophrenia and cocaine use disorder.”
BackgroundBipolare Störungen und Abhängigkeitserkrankungen
Wong, M. W., & Preuss, U. W. (2009) · Nervenheilkunde · doi:10.1055/s-0038-1628671 · Cited by 6
“Die gleiche Arbeitsgruppe unternahm im Rahmen von kontrollierten Studien Behandlungsversuche mit moderneren Antipsychotika, nämlich Quetiapin (6) und Aripiprazol (5).”
BackgroundReview of the efficacy of treatments for bipolar disorder and substance abuse
Secades-Álvarez, A., & Fernández, C. (2017) · Revista de Psiquiatría y Salud Mental (English Edition) · doi:10.1016/j.rpsmen.2017.05.002 · Cited by 8
Thurstone, C., Loh, R. M., Foreman, K., Thurstone, C., & Wolf, C. (2023) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2023.0053 · Cited by 5
“Finally, small clinical trials generally support the use of aripiprazole for alcohol use disorder and cocaine use disorder (Anton et al., 2008; Beresford et al., 2005; Brown et al., 2005).”
Secades-Álvarez, A., & Fernández, C. (2015) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.rpsm.2015.10.003 · Cited by 11
Costentin, J. (2009) · L Encéphale · doi:10.1016/j.encep.2008.12.001 · Cited by 4
The pharmacological management of gambling disorder: if, when, and how
Pettorruso, M., Carlo, F. D., Romeo, V. M., Jiménez‐Múrcia, S., Grant, J. E., Martinotti, G., & Giannantonio, M. D. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2172329 · Cited by 7
“The most relevant are substance use disorders (SUDs), especially alcohol use disorder (AUD) and nicotine dependence, as well as mood disorders, personality disorders, ADHD, and impulse-control disorders [7,8].”
BackgroundInfluentialChronic Psychosis in Dual Disorder Heroin Use Disorder Patients
Maremmani, I., Pacini, M., & Maremmani, A. G. I. (2023) · Springer eBooks · doi:10.1007/978-3-031-30093-6_4 · Cited by 6
Pharmacotherapy Options in Comorbid Bipolar Disorder and Alcohol-Substance Use Disorders
Altınbaş, K., & Evren, C. (2013) · Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology · doi:10.5455/bcp.20131122111840 · Cited by 7
“There was significant improvement in baseline scores at the end of the trial and patients with alcohol/cocaine dependence had a significant decrease in craving (56).”
BackgroundInfluentialCo-morbid Bipolar and Alcohol Use Disorders: A Treatment-Focused Review
Prisciandaro, J. J., & Myrick, D. H. (2010) · Journal of Dual Diagnosis · doi:10.1080/15504261003701858 · Cited by 3
“One open-label study examined the potential utility of aripiprazole in treating co-morbid bipolar disorder and alcohol dependence ( Brown, Jeffress, Liggin, Garza, & Beard, 2005 ).”
BackgroundTolliver, B. K., & Hartwell, K. J. (2012) · Psychiatric Annals · doi:10.3928/00485713-20120507-07 · Cited by 4
Utility of aripiprazole in co-occurring problem gambling and toluene dependence: A case report
Modak, T., Bhad, R., & Rao, R. (2018) · Journal of Substance Use · doi:10.1080/14659891.2018.1523964 · Cited by 3
Nicola, M. D., Moccia, L., Ferri, V. R., Panaccione, I., & Janiri, L. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813125-1.00038-6 · Cited by 4
Olanzapina in pazienti maniacali o misti con o senza abuso di sostanze
Sani, G., Simonetti, A., Serra, G., Solfanelli, A., Girardi, N., Janiri, D., Danese, E., Rapinesi, C., Tatarelli, R., & Girardi, P. (2013) · Rivista di psichiatria · doi:10.1708/1272.14038 · Cited by 3
Limosin, F., Azorin, J., Krebs, M., Millet, B., Glikman, J., Camus, V., Crocq, M. A., Costentin, J., & Jean Dalery, A. (2008) · L Encéphale · doi:10.1016/j.encep.2007.12.003 · Cited by 2
Shabkhaneh, R. Z., Ardakani, M. R. K., Karimlou, M., & Mahdi, R. (2017) · نشریه روان پرستاری · doi:10.21859/ijpn-05056 · Cited by 2
Aripiprazole: an appraisal of the translation of complex receptor effects into clinical outcomes
Buckley, P. F., & Sebastian, S. (2005) · Therapy · doi:10.1586/14750708.2.5.699 · Cited by 2
Chapter 49. Schizophrenia Spectrum and Other Psychotic Disorders
Schwartz, E., Brunette, M. F., & Green, A. I. (2021) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615373970.kb49 · Cited by 2
Dopamine Receptors: Neurotherapeutic Targets for Substance Use Disorders
Nilson, A. N., Felsing, D. E., & Allen, J. (2022) · Wiley eBooks · doi:10.1002/9781119564782.ch19 · Cited by 3
Metadata
- Authors
- Brown, E. S., Jeffress, J., Liggin, J. D. M., Garza, M., & Beard, L.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- ORCID
- Brown, E. Sherwood
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2005-06-15
- Volume
- 66
- Issue
- 06
- Pages
- 756-760
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2004252407
- Cited by
- 118
- References
- 0
- Citations by year
- 2024: 3 · 2023: 4 · 2022: 2 · 2021: 5 · 2019: 4 · 2018: 8 · 2017: 7 · 2016: 4 · 2015: 3 · 2014: 6 · 2013: 5 · 2012: 8
- FWCI
- 6.45
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- aripiprazole, bipolar disorder, schizoaffective disorder, substance abuse, dual diagnosis, antipsychotic switching, alcohol craving, cocaine craving, alcoholism, cocaine dependence, mania, depression, antipsychotic adverse effects, akathisia
- MeSH terms
- Aripiprazole, Adult, Ambulatory Care, Bipolar Disorder, Female, Humans, Male, Pilot Projects, Piperazines, Psychiatric Status Rating Scales, Psychotic Disorders, Antipsychotic Agents, Quinolones, Comorbidity, Treatment Outcome, Receptors, Dopamine D2, Diagnosis, Dual (Psychiatry), Dopamine Agonists, Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.